Register Free
Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Diabetes / Metabolic Neurology Rheumatology Women's Health Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Trial Radar • ClinicalTrials.gov • Registry-linked

Trial Radar

1963 clinical trials with phase, status, specialty and registry links, summarised for rapid clinical review.

1963 recruiting AI clinical summaries
Explore Trial Collections Follow research updates
All Phases Phase I Phase II Phase III Phase IV
Therapeutic Area: All Cardiology / Cardiovascular Dermatology Diabetes / Metabolic Gastroenterology Haematology Infectious Disease Men's Health Mental Health / Psychiatry Nephrology Neurology Oncology Rare Diseases
🔬
Trial Radar

Clinical Trial Intelligence

● Recruiting Phase II
A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves’ Disease
New drug IMVT-1402 tested against placebo in patients with Graves' disease uncontrolled by standard thyroid medications.
08 Jun 2026 NCT07018323
active not recruiting Phase II Oncology
A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Trial testing niraparib combined with other drugs to treat advanced prostate cancer resistant to hormone therapy.
08 Jun 2026 NCT03431350
active not recruiting Phase II Respiratory / COPD / Asthma
A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.
Buloxibutid tested against placebo over 52 weeks in IPF patients to assess whether it slows lung function decline and is safe to use.
05 Jun 2026 NCT06588686
active not recruiting Phase II Neurology
A Study to Learn About the Safety of BIIB080 Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer’s Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age
Trial testing BIIB080 injections to slow cognitive decline in people aged 50-80 with mild Alzheimer's disease or mild cognitive impairment.
05 Jun 2026 NCT05399888
active not recruiting Phase I / Phase II Diabetes / Metabolic
A Safety, Tolerability, and Efficacy Study of VX-264 in Participants With Type 1 Diabetes
VX-264 trial tested a new drug's safety and effectiveness in type 1 diabetes patients.
04 Jun 2026 NCT05791201
● Recruiting Phase II
A Safety and Efficacy Study of GTX-102 in Subjects With Deletion- or Nondeletion-type Angelman Syndrome (AS)
GTX-102 injection being tested for safety and effectiveness in treating Angelman syndrome caused by different genetic mutations.
04 Jun 2026 NCT07157254
● Recruiting Phase II Oncology
A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer
What is being tested: Inavolisib (a PI3K inhibitor) combined with enzalutamide versus standard physician-selected alternatives (other androgen receptor pathway inhibitors or docetaxel) in biomarker-selected…
04 Jun 2026 NCT07287150
● Recruiting Phase II Respiratory / COPD / Asthma
Volatile Sedation for Patients With the Acute Respiratory Distress Syndrome
What is being tested: The trial compares volatile anaesthetic sedation against conventional intravenous sedation approaches in mechanically ventilated ICU patients to evaluate effects on…
04 Jun 2026 NCT06014138
● Recruiting Phase II
A Study of the Safety and Activity of Sparsentan for the Treatment of Patients With Immunoglobulin A Nephropathy
What is being tested: Sparsentan, a dual endothelin and angiotensin II receptor antagonist, is being evaluated for its nephroprotective efficacy and safety in patients…
03 Jun 2026 NCT04663204
● Recruiting Phase II Rheumatology
A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH – SLE/LN)
What is being tested: Rapcabtagene autoleucel, a one-time CAR-T cell therapy administered after lymphodepletion, in patients with active, treatment-refractory systemic lupus erythematosus or lupus…
03 Jun 2026 NCT06581198
● Recruiting Phase II Cardiology / Cardiovascular
A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis
What is being tested: LTI-03, an inhaled experimental medication designed to treat Idiopathic Pulmonary Fibrosis (IPF) by addressing the underlying pathophysiology of progressive lung…
03 Jun 2026 NCT06968845
active not recruiting Phase I / Phase II Dermatology
Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)
Trial testing epcoritamab alone or combined with other drugs for B-cell non-Hodgkin lymphoma across ten treatment arms.
02 Jun 2026 NCT04663347
● Recruiting Phase II Oncology
Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype
What is being tested: Trastuzumab deruxtecan (T-DXd), an antibody-drug conjugate, is being compared against standard CDK4/6 inhibitor-based endocrine therapy as first-line treatment for HR-positive/HER2-low…
02 Jun 2026 NCT06486883
● Recruiting Phase II
Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders
Tafasitamab was tested in adults with autoimmune blood disorders to assess whether it was safe and effective.
01 Jun 2026 NCT07104565
active not recruiting Phase II
A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma
TrAVeRse Trial Summary Acalabrutinib, venetoclax and rituximab combination therapy for untreated mantle cell lymphoma, testing whether maintenance treatment improves outcomes.
01 Jun 2026 NCT05951959
● Recruiting Phase II Respiratory / COPD / Asthma
Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis
What is being tested: PIPE-791, a novel investigational agent, is being evaluated in a Phase 2 randomised controlled trial to assess its efficacy, safety,…
01 Jun 2026 NCT07284459
● Recruiting Phase I / Phase II
A Study of AAVB-039 in Participants With Stargardt Disease (STGD1)
Gene therapy injection for Stargardt disease shows safety and early effectiveness in patients with ABCA4 gene mutations.
29 May 2026 NCT07161544
active not recruiting Phase I / Phase II Oncology
A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma
Early-stage trial testing new cancer drug englumafusp alfa combined with existing treatments in patients with relapsed/refractory lymphoma.
29 May 2026 NCT04077723
● Recruiting Phase II Rheumatology
A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)
Trial testing whether new drug BI 3000202 at different doses improves lupus symptoms in adults over one year.
29 May 2026 NCT07409181
● Recruiting Phase II Oncology
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
What is being tested: This trial investigates ribociclib (CDK4/6 inhibitor) combined with either everolimus or temozolomide in pediatric and young adult patients with newly…
29 May 2026 NCT05843253
active not recruiting Phase I / Phase II Oncology
A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101)
MTAPESTRY 101 Summary Trial testing anvumetostat drug alone and with chemotherapy in patients with MTAP-null cancers to find safe doses and effectiveness.
28 May 2026 NCT05094336
● Recruiting Phase II Oncology
Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer
Treatment being tested: Camizestrant (an ER degrader) combined with atirmociclib (a CDK4/6 inhibitor) in women with ER-positive, HER2-negative advanced breast cancer who have previously…
28 May 2026 NCT07427394
● Recruiting Phase II Mental Health / Psychiatry
An Open-Label Study to Evaluate the Safety, Tolerability and Pharmacodynamics of BPL-003 in Patients With Treatment Resistant Depression
BPL-003 Trial Summary Intranasal BPL-003 with psychological support tested for safety and effectiveness in treatment-resistant depression, used alone or with SSRIs.
26 May 2026 NCT05660642
● Recruiting Phase I / Phase II
A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet Syndrome
ETX101 gene therapy trial testing safety and effectiveness in infants and children with Dravet syndrome.
26 May 2026 NCT05419492
● Recruiting Phase II Oncology
Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors
What is being tested: Volrustomig, a novel anti-cancer agent, is being evaluated both as a standalone treatment and combined with existing anti-cancer drugs in…
26 May 2026 NCT06535607
● Recruiting Phase II
A Study of LY4005130 in Adult Participants With Severe Alopecia Areata (Hair Loss)
Trial testing new drug LY4005130 versus placebo for severe hair loss, measuring effectiveness, safety, and how body processes drug.
22 May 2026 NCT07533006
● Recruiting Phase II
A Study to Investigate the Efficacy and Safety of Rilzabrutinib in Adult Participants With Graves’ Disease
A trial testing whether rilzabrutinib improves Graves' disease symptoms and safety over 16 weeks in two dose groups.
22 May 2026 NCT06984627
● Recruiting Phase II Oncology
Investigating Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-negative Metastatic Triple-negative Breast Cancer
Treatment Being Tested: Datopotamab deruxtecan (Dato-DXd) monotherapy versus Dato-DXd combined with the immunotherapy agent durvalumab in patients with PD-L1-negative metastatic triple-negative breast cancer (TNBC).…
22 May 2026 NCT06954480
active not recruiting Phase II
Study of Ibrutinib + CD20 Antibody and Venetoclax in Patients With Untreated Mantle Cell Lymphoma
Trial comparing two drug combinations for newly diagnosed mantle cell lymphoma, measuring minimal disease status at six months.
20 May 2026 NCT04802590
● Recruiting Phase II Respiratory / COPD / Asthma
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
What is being tested: Adagrasib (MRTX849), a KRAS G12C inhibitor, evaluated as monotherapy and combined with pembrolizumab (anti-PD-L1 immunotherapy) in patients with advanced non-small…
20 May 2026 NCT04613596
● Recruiting Phase II Respiratory / COPD / Asthma
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
What is being tested: Adagrasib (MRTX849), a targeted KRAS G12C inhibitor, is being evaluated as monotherapy and in combination with the immunotherapy pembrolizumab in…
20 May 2026 NCT04613596
● Recruiting Phase II Cardiology / Cardiovascular
Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA
What is being tested: Rapcabtagene autoleucel, a CAR-T cell therapy, is being evaluated for efficacy and safety in treating severe active GPA (Granulomatosis with…
20 May 2026 NCT06868290
● Recruiting Phase II Cardiology / Cardiovascular
Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA
Treatment being tested: Rapcabtagene autoleucel, a CAR-T cell therapy, is being evaluated against a comparator treatment in patients with severe active GPA or MPA—rare…
20 May 2026 NCT06868290
● Recruiting Phase II Oncology
Visugromab in Cachexia International Trial
What is being tested: Visugromab, a novel therapeutic agent, is being evaluated for safety and efficacy in treating cancer-associated cachexia (unintended weight loss) across…
20 May 2026 NCT07112196
● Recruiting Phase II Oncology
A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery
Intervention Being Tested: Radspherin® (a single intraperitoneal injection) is being evaluated as an adjunct to standard neoadjuvant chemotherapy and interval debulking surgery in patients…
20 May 2026 NCT06504147
● Recruiting Phase II Oncology
A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery
What is being tested: Radspherin® (a single intraperitoneal injection) is being evaluated for efficacy and safety in patients with primary advanced high-grade serous or…
20 May 2026 NCT06504147
● Recruiting Phase II Oncology
Visugromab in Cachexia International Trial
What is being tested: Visugromab, a novel therapeutic agent, is being evaluated for efficacy and safety in managing cancer-associated cachexia (unintended weight loss) across…
20 May 2026 NCT07112196
active not recruiting Phase II
A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (ALS)
Testing whether VHB937 drug slows early ALS progression compared to placebo over 40 weeks, then all patients receive active treatment.
19 May 2026 NCT06643481
active not recruiting Phase II Respiratory / COPD / Asthma
Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)
A study testing a new drug (tulisokibart) to treat scleroderma patients with lung scarring to see if it's safe and effective.
18 May 2026 NCT05270668
● Recruiting Phase II Oncology
A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer
What is being tested: A triplet combination therapy of inavolisib (PI3K inhibitor) added to ribociclib (CDK4/6 inhibitor) and fulvestrant (endocrine therapy) compared to standard…
18 May 2026 NCT07405801
active not recruiting Phase II Oncology
Nivolumab in Patients With Type B3 Thymoma and Thymic Carcinoma (NIVOTHYM)
Nivolumab showed activity and tolerable side-effects in previously-treated thymic carcinoma and B3 thymoma patients.
15 May 2026 NCT03134118
● Recruiting Phase II Oncology
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
What is being tested: HER3-DXd monotherapy, a targeted antibody-drug conjugate (ADC) directed against HER3, is being evaluated as a single-agent treatment in locally advanced…
15 May 2026 NCT06172478
● Recruiting Phase II Respiratory / COPD / Asthma
Phase 2 Study of Rapcabtagene Autoleucel in Myositis
What is being tested: Rapcabtagene autoleucel, a CAR T-cell therapy, is being evaluated against a comparator treatment in patients with severe refractory idiopathic inflammatory…
15 May 2026 NCT06665256
active not recruiting Phase I / Phase II
INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders
Trial testing INCB000928 alone or with ruxolitinib to treat anemia in myelofibrosis patients, assessing safety and effectiveness.
14 May 2026 NCT04455841
● Recruiting Phase II Oncology
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
What is being tested: Ficerafusp alfa (a dual EGFR/TGF-β targeted therapy) combined with pembrolizumab versus pembrolizumab alone as first-line treatment for PD-L1-positive recurrent or…
14 May 2026 NCT06788990
● Recruiting Phase II Oncology
Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
What is being tested: Novel combination therapies (multi-drug regimens) evaluated for efficacy, safety, tolerability, pharmacokinetics, and immunogenicity in gastric and gastroesophageal junction adenocarcinoma. Patient…
14 May 2026 NCT05702229
active not recruiting Phase II Neurology
Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD
New drug BIA 28-6156 tested against placebo to slow motor decline in GBA gene-linked Parkinson's disease over 78 weeks.
13 May 2026 NCT05819359
active not recruiting Phase II Neurology
A Study of JNJ-64042056 in Participants With Preclinical Alzheimer’s Disease
An experimental drug tested to see if it slows tau protein buildup in early Alzheimer's disease using brain scanning.
13 May 2026 NCT06544616
active not recruiting Phase II Diabetes / Metabolic
A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related Comorbidity
A new drug combined with tirzepatide tested against tirzepatide alone for weight loss in overweight or obese adults over 48 weeks.
13 May 2026 NCT06965413
● Recruiting Phase II Dermatology
A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Diarrhea (IBS-D)
A 35-week trial testing whether brenipatide injections improve symptoms and are safe in patients with IBS-diarrhea compared to placebo.
13 May 2026 NCT07545759